Vir Biotechnology (VIR) Net Cash Flow (2018 - 2026)

Vir Biotechnology has reported Net Cash Flow for 9 years, with the latest figure at $42.0 million in Q1 2026.

• Quarterly Net Cash Flow fell 14.86% year-over-year to $42.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$85.0 million (down 145.3% YoY) and the FY2025 annual result came in at -$77.6 million, down 235.23% from the prior year.
• Net Cash Flow retreated to $42.0 million in Q1 2026 per VIR's latest filing, from $61.8 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $690.9 million in Q2 2022 and troughed at -$542.7 million in Q3 2022.
• A 5-year average of -$4.7 million and a median of -$52.8 million in 2024 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 452.44% in 2022, down 1816.04% in 2022.
• Over 5 years, Net Cash Flow stood at -$116.0 million in 2022, then plunged by 81.95% to -$211.1 million in 2023, then soared by 125.76% to $54.4 million in 2024, then advanced by 13.7% to $61.8 million in 2025, then slumped by 32.1% to $42.0 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $42.0 million, $61.8 million, and -$127.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.